[Platelet aggregation inhibitors and anticoagulants during ophthalmic interventions]

Area of Science:

• Ophthalmology
• Cardiology
• Pharmacology

Background:

• Many patients requiring ophthalmic surgery are on anticoagulant therapy for cardiovascular conditions.
• Managing anticoagulant medication perioperatively involves balancing thromboembolism risk against surgical hemorrhage risk.
• Established guidelines exist for thromboembolism risk assessment, but data on hemorrhage risk in ophthalmic surgery is limited.

Purpose of the Study:

• To review current knowledge on the perioperative use of anticoagulant drugs in ophthalmology.
• To present and discuss data concerning the risk of hemorrhage in ophthalmic surgical procedures.
• To provide evidence-based recommendations for managing anticoagulant therapy in patients undergoing eye surgery.

Main Methods:

• Literature review of existing studies and clinical practice guidelines.
• Analysis of data on hemorrhage risks associated with various ophthalmic surgical interventions.
• Comparison of thromboembolism risk versus bleeding risk in the context of ophthalmic surgery.

Main Results:

• Ophthalmic surgery generally presents a low risk of bleeding compared to other surgical fields.
• Existing data suggests that discontinuing anticoagulant therapy is often unnecessary for patients undergoing ophthalmic surgery.
• Current clinical practice may overestimate the need to alter anticoagulant regimens for these patients.

Conclusions:

• In most cases, patients on anticoagulant medication can continue their therapy during ophthalmic surgery without increased risk.
• The risk of thromboembolic events from discontinuing anticoagulation may outweigh the low risk of surgical bleeding.
• Further research and updated guidelines are needed to refine perioperative anticoagulant management in ophthalmology.